Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Open access

Abstract

Background Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with Down syndrome, but the natural history of biomarker changes in Down syndrome has not been established. We characterised the order and timing of changes in biomarkers of Alzheimer's disease in a population of adults with Down syndrome. Methods We did a dual-centre cross-sectional study of adults with Down syndrome recruited through a population-based health plan in Barcelona (Spain) and through services for people with intellectual disabilities in Cambridge (UK). Cognitive impairment in participants with Down syndrome was classified with the Cambridge Cognitive Examination for Older Adults with Down Syndrome (CAMCOG-DS). Only participants with mild or moderate disability were included who had at least one of the following Alzheimer's disease measures: apolipoprotein E allele carrier status; plasma concentrations of amyloid β peptides 1–42 and 1–40 and their ratio (Aβ 1–42/1–40 ), total tau protein, and neurofilament light chain (NFL); tau phosphorylated at threonine 181 (p-tau), and NFL in cerebrospinal fluid (CSF); and one or more of PET with 18 F-fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative on Neurodegeneration. We used a first-order locally estimated scatterplot smoothing curve to determine the order and age at onset of the biomarker changes, and the lowest ages at the divergence with 95% CIs are also reported where appropriate. Findings Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls. CSF Aβ 1–42/1–40 and plasma NFL values changed in individuals with Down syndrome as early as the third decade of life, and amyloid PET uptake changed in the fourth decade. 18 F-fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth decade of life, followed by hippocampal atrophy and changes in cognition in the fifth decade of life. Prodromal Alzheimer's disease was diagnosed at a median age of 50·2 years (IQR 47·5–54·1), and Alzheimer's disease dementia at 53·7 years (49·5–57·2). Symptomatic Alzheimer's disease prevalence increased with age in individuals with Down syndrome, reaching 90–100% in the seventh decade of life. Interpretation Alzheimer's disease in individuals with Down syndrome has a long preclinical phase in which biomarkers follow a predictable order of changes over more than two decades. The similarities with sporadic and autosomal dominant Alzheimer's disease and the prevalence of Down syndrome make this population a suitable target for Alzheimer's disease preventive treatments. Funding Instituto de Salud Carlos III, Fundació Bancaria La Caixa, Fundació La Marató de TV3, Medical Research Council, and National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30689-9

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Clinical and neuropsychological changes with age in adults with Down syndrome (A) Point prevalence of Alzheimer's disease dementia, prodromal Alzheimer's disease, and no clinical symptoms of Alzheimer's disease in individuals with Down syndrome. (B) Age-related changes in CAMCOG-DS scores in individuals with Down syndrome with mild or moderate intellectual disability (analysed separately), with bands representing 95% CIs. The vertical dashed line at 50·2 years represents the median age at the expected symptom onset (ie, prodromal Alzheimer's disease diagnosis). CAMCOG-DS=Cambridge Cognitive Examination for Older Adults with Down Syndrome.
Figure 1 Clinical and neuropsychological changes with age in adults with Down syndrome (A) Point prevalence of Alzheimer's disease dementia, prodromal Alzheimer's disease, and no clinical symptoms of Alzheimer's disease in individuals with Down syndrome. (B) Age-related changes in CAMCOG-DS scores in individuals with Down syndrome with mild or moderate intellectual disability (analysed separately), with bands representing 95% CIs. The vertical dashed line at 50·2 years represents the median age at the expected symptom onset (ie, prodromal Alzheimer's disease diagnosis). CAMCOG-DS=Cambridge Cognitive Examination for Older Adults with Down Syndrome.CC BY-NC-ND · PubMed Central
Figure 2 Imaging signature of Alzheimer's disease in adults with Down syndrome for brain structure, glucose metabolism, and amyloid β deposition All panels compare individuals with Down syndrome with symptomatic Alzheimer's disease with those with no clinical evidence of dementia. The left panel represents loss of cortical thickness, the middle panel loss of brain glucose metabolism, and the right panel the increase in cerebral fibrillar amyloid β deposition.
Figure 2 Imaging signature of Alzheimer's disease in adults with Down syndrome for brain structure, glucose metabolism, and amyloid β deposition All panels compare individuals with Down syndrome with symptomatic Alzheimer's disease with those with no clinical evidence of dementia. The left panel represents loss of cortical thickness, the middle panel loss of brain glucose metabolism, and the right panel the increase in cerebral fibrillar amyloid β deposition.CC BY-NC-ND · PubMed Central
Figure 3 Biomarker changes with age in adults with Down syndrome and control participants Shading represents 95% CIs. The vertical dashed lines at 50·2 years represent the age at the expected symptom onset (eg, median age of prodromal Alzheimer's disease diagnosis). Aβ1–40=amyloid β peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CSF=cerebrospinal fluid. FDG=18F-fluorodeoxyglucose. NFL=neurofilament light chain. SUVR=standardised uptake value ratio.
Figure 3 Biomarker changes with age in adults with Down syndrome and control participants Shading represents 95% CIs. The vertical dashed lines at 50·2 years represent the age at the expected symptom onset (eg, median age of prodromal Alzheimer's disease diagnosis). Aβ1–40=amyloid β peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CSF=cerebrospinal fluid. FDG=18F-fluorodeoxyglucose. NFL=neurofilament light chain. SUVR=standardised uptake value ratio.CC BY-NC-ND · PubMed Central
Figure 4 Integrated model of the natural history of Alzheimer's disease in individuals with Down syndrome Comparison of structural, metabolic, and biochemical biomarker changes as a function of age by use of the standardised differences between participants with Down syndrome and controls fitted with a locally estimated scatterplot smoothing curve. Positive standardised differences represent higher biomarker values in participants with Down syndrome than in euploid controls, and negative values represent lower biomarker values. The vertical dashed line at 50·2 years represents the age at the expected symptom onset (median age of prodromal Alzheimer's disease diagnosis). Aβ1–40=amyloid β peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CAMCOG-DS=Cambridge Cognitive Examination for Older Adults with Down Syndrome. CSF=cerebrospinal fluid. NFL=neurofilament light chain. p-tau=tau phosphorylated at threonine 181.
Figure 4 Integrated model of the natural history of Alzheimer's disease in individuals with Down syndrome Comparison of structural, metabolic, and biochemical biomarker changes as a function of age by use of the standardised differences between participants with Down syndrome and controls fitted with a locally estimated scatterplot smoothing curve. Positive standardised differences represent higher biomarker values in participants with Down syndrome than in euploid controls, and negative values represent lower biomarker values. The vertical dashed line at 50·2 years represents the age at the expected symptom onset (median age of prodromal Alzheimer's disease diagnosis). Aβ1–40=amyloid β peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CAMCOG-DS=Cambridge Cognitive Examination for Older Adults with Down Syndrome. CSF=cerebrospinal fluid. NFL=neurofilament light chain. p-tau=tau phosphorylated at threonine 181.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 373

Metadata

Authors
Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., Valldeneu, S., Giménez, S., González-Ortiz, S., Muñoz, L., Estellés, T., Illán-Gala, I., Belbin, O., Camacho, V., Wilson, L. R., Annus, T., Osorio, R. S., Videla, S., Lehmann, S., Holland, A. J., Alcolea, D., Clarimón, J., Zaman, S. H., Blesa, R., & Lleó, A.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • Hospital de Sant Pau (ES)
  • University of Cambridge (GB)
  • NYU Langone Health (US)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Inserm (FR)
Corresponding author
Fortea, Juan
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-06
Volume
395
Issue
10242
Pages
1988-1997
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3038008717
Cited by
340
References
37
Citations by year
2026: 43 · 2025: 74 · 2024: 57 · 2023: 43 · 2022: 61 · 2021: 53 · 2020: 9
FWCI
31.31
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc-nd)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by-nc-nd)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
  • Apollo
Funders
  • Fundació la Marató de TV3
  • Global Brain Health Institute
  • Generalitat de Catalunya
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
  • National Institutes of Health (2013-2016)
  • Instituto de Salud Carlos III (2013-2016)
  • European Regional Development Fund
  • National Institute on Aging (P30AG066512)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, Down syndrome, biomarkers, natural history (disease), amyloid PET, neurofilament light chain, apolipoprotein E, total tau, cognitive impairment, prodromal Alzheimer's disease, dementia
MeSH terms
Adult, Alzheimer Disease, Amyloidosis, Apolipoproteins E, Cross-Sectional Studies, Down Syndrome, United Kingdom, Humans, Magnetic Resonance Imaging, Middle Aged, Spain, Biomarkers, Prevalence, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins, Fluorodeoxyglucose F18, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30689-9
The paper
Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., Valldeneu, S., Giménez, S., González-Ortiz, S., Muñoz, L., Estellés, T., Illán-Gala, I., Belbin, O., Camacho, V., Wilson, L. R., . . . Lleó, A. (2020). Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. The Lancet. https://doi.org/10.1016/s0140-6736(20)30689-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.